Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study. Zhong R, Chu T, Xiong L, Shi C, et al. Int J Cancer 2025;157:549-558.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhong R, Chu T, Xiong L, Shi C, et al. Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study. Int J Cancer 2025;157:549-558.
PMID: 40135473